T. Rowe Price Investment Management, Inc. Immatics N.V. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Immatics N.V. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 18,328,455 shares of IMTX stock, worth $118 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
18,328,455
Previous 14,677,003
24.88%
Holding current value
$118 Million
Previous $66.2 Million
48.97%
% of portfolio
0.06%
Previous 0.04%
Shares
9 transactions
Others Institutions Holding IMTX
# of Institutions
73Shares Held
93.6MCall Options Held
158KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY12MShares$77.2 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY10.2MShares$65.3 Million0.55% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$60.2 Million2.22% of portfolio
-
Rtw Investments, LP New York, NY6.97MShares$44.7 Million0.58% of portfolio
-
Vestal Point Capital, LP New York, NY6.25MShares$40.1 Million1.77% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $489M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...